Breast Cancer: FDA Considers Avastin Withdrawal

New evidence suggests the risks outweigh the benefits of Avastin for treating metastatic breast cancer, according to officials at the U.S. Food and Drug Administration. The agency has now begun the process of withdrawal of the popular advanced breast cancer treatment. The FDA granted an accelerated conditional approval for Avastin in February 2008 to treat late-stage breast cancer patients. The drug, it had been suggested, slowed the progression of the disease or improved overall survival. ...Full Story
Commenting on this article is closed.